Objective: To evaluate the accuracy and clinical utility of phosphorylated tau (p-tau) for the diagnosis and prognosis of Alzheimer’s disease (AD) and mild cognitive impairment (MCI).
Methods: A meta-analysis was performed of 19 robust studies that compared AD with healthy individuals (n = 2300), 18 that compared AD with non-AD dementias (n = 1892), eight that compared MCI with healthy subjects (n = 447) and six in those with MCI who did and did not progress to dementia (n = 388).
Results: On the basis of levels of p-tau in CSF, AD could be discriminated from those without cognitive impairment with a sensitivity (Se) of 77.6%, a specificity (Sp) of 87.9%, a positive predictive value (PPV) of 90.3% and a negative predictive value (NPV) of 73.0%. The clinical utility of the test was rated as “good”. CSF levels of p-tau separated AD from other dementias with an Se of 71.6% and an Sp 77.8% but here the clinical utility was satisfactory to poor. Regarding MCI, p-tau contributed to the separation of MCI from healthy individuals with an Se of 79.6% and an Sp 83.9% (PPV 85.9%, NPV 76.9%). Here the clinical utility was rated as “satisfactory”. P-tau was modestly successful in predicting progression to dementia in MCI (Se 81.1%, Sp 65.3%, PPV 63.0%, NPV 83.0%), showing higher predictive value for absence of progression rather than conversion to AD.
Conclusions: CSF p-tau is a good diagnostic biomarker of probable AD, a satisfactory diagnostic biomarker of MCI, a satisfactory prognostic biomarker for progression of MCI but was less adequate in separating AD from other dementias.
Statistics from Altmetric.com
Competing interests None.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.